5Yee LJ, Tang J, Herrera J, et al. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection.Genes Immun, 2000, 1: 386-390.
6Miyazoe S, Hamasaki K, Nakata K, et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus.Am J Gastroenterol,2002, 97: 2086-2092.
7Gewaltig J, Mangasser-Stephan K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-betal gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta, 2002, 316: 83-94.
8Chau TK, Marakami S, Kawai B, et al. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma. Life Sci, 2000, 67: 1719-1724.
9Mckiernan S, Daly J, Curry MP, et al.Polymorphisms of the TNF-a gene promoter region in hepatitis C infection. Hepatology, 1999,30: 360.
10Vidigal PG, Germer J J, Zein NN. Polymorphisms in the interleukin-10, tumor necrosis factor-alpha, and transforming growth factorbetal genes in chronic hepatitis C patients treated with interferon and ribavirin. J Hepatol, 2002, 36: 271-277.
5Loupy A, Viglietti D, Mengel M. Complement Inhibition in HLA- Incompatible Kidney Transplants: Persisting Antibody-Mediated In- jury Despite Marked Decrease of Clinical ABMR. Am J Trans- plant, 2015,15(5) :1139-1140.
6Jung M C, Pape G R. Immunology of hepatitis B infection. Lancet Infect Dis,2002, 2(1) : 43-50.
7Thio C L, Seaberg E C, Skolasky R J, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Muhicenter Cohort Study(MACS).Lancet.2002,360(9349):1921-1926.
